IKT vs. DNTH, IOVA, ABUS, AKBA, ZYBT, EOLS, XNCR, ABCL, CDXC, and KALV
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), Zhengye Biotechnology (ZYBT), Evolus (EOLS), Xencor (XNCR), AbCellera Biologics (ABCL), ChromaDex (CDXC), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.
Inhibikase Therapeutics vs.
Dianthus Therapeutics (NASDAQ:DNTH) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
Inhibikase Therapeutics has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.
Inhibikase Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Inhibikase Therapeutics' return on equity.
In the previous week, Dianthus Therapeutics had 14 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 16 mentions for Dianthus Therapeutics and 2 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.82 beat Dianthus Therapeutics' score of 0.53 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.
Dianthus Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Dianthus Therapeutics received 19 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. Likewise, 96.55% of users gave Dianthus Therapeutics an outperform vote while only 75.00% of users gave Inhibikase Therapeutics an outperform vote.
Dianthus Therapeutics currently has a consensus price target of $53.00, indicating a potential upside of 182.67%. Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 229.95%. Given Inhibikase Therapeutics' higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Dianthus Therapeutics.
47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 8.2% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 4.6% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Dianthus Therapeutics beats Inhibikase Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:IKT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy IKT Stock Free IKT Stock Alerts